Alvotech (ALVO) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 20-F filed 2026-03-31

How it makes money

Partners pay royalties and milestone payments to Alvotech for using its biosimilar intellectual property.

Alvotech develops biosimilars, which are biological medicines highly similar to existing products with expired patents.

Instead of selling drugs directly, the company licenses its intellectual property to commercialization partners. These partners pay Alvotech royalties on sales and milestone payments as products reach development targets.

What protects it: the moat

Management claims a vertically integrated platform provides advantages in quality, cost, and speed to market.

Alvotech is a vertically integrated company, meaning it handles everything from research and development to manufacturing in-house.

Management claims this approach allows the company to capture efficiencies that provide advantages in quality, cost, and speed to market.

What growth costs

The company invests heavily in its manufacturing and research infrastructure in Iceland.

The company spends significant capital on property, plant and equipment, lab equipment, and computer equipment in Iceland.

Actual capital expenditures were $64.5 million in 2025, $53.7 million in 2024, and $33.2 million in 2023.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Other companies in Drug Manufacturers - Specialty & Generic